Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 399-408

  Tortella, Frank C ^a   Britton, Paul ^a   Williams, Anthony ^a   Lu, Xi Chung May ^a   Newman, Amy H ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AHN 649; DEXTROMETHORPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; SEIZURE;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY AMINO ACIDS; MALE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; REPERFUSION;

EID: 0032849033     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bederson JB, Pitts LH, Tsuh M, Nishmura MC, Davis RL and Bartkowski H (1986) Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurological examination. Stroke 17:472-476.
2. Britton P, Lu May X-C, Laskosky MS and Tortella FC (1997) Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci 60:1729-1740.
3. Clemens JA and Panetta JA (1994) Neuroprotection by antioxidants in models of global and focal ischemia. Ann NY Acad Sci 738:250-256.
4. Cregan EF, Peeling J, Corbett D, Buchan AM, Saunders J, Auer RN, Gao M, McCarthy DJ, Eisman MS, Campell TM, Murray RJ, Stagnitto ML and Palmer GC (1997) [(S)-α-Phenyl-2-pyridine-ethanamine dihydrochloride], a low-affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia. J Pharmacol Exp Ther 239:1412-1424.
5. Crowell RM, Olsson Y, Klatzo I and Ommaya A (1970) Temporary occlusion of the middle cerebral artery in the monkey: Clinical and pathological observations. Stroke 1:439-448.
6. 2 ligands. Synapse 29:62-71.
7. DeCoster MA, Klette KL, Knight ES and Tortella FC (1995) Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671:45-53.
8. Dezsi L, Greenberg JH, Hamar J, Sladky J, Karp A and Reivich M (1992) Acute improvement in the histological outcome by MK-801 following focal cerebral ischemic and reperfusion in the cat independent of blood flow changes. J Cereb Blood Flow Metab 12:390-399.
9. Echevarria E, Robles L and Tortella FC (1990) Differential profiles of putative "dextromethorphan sigma" ligands in experimental seizure models. Fed Proc 4:A311.
10. Halsey JH, Conger KA, Garcia JH and Sarvary E (1991) The contribution of reoxygenation to ischemic brain damage. J Cereb Blood Flow Metab 11:994-1000.
11. Hallenbeck JM and Dutka AJ (1990) Background review and current concepts of reperfusion injury. Arch Neurol 47:1245-1254.
12. Hargreaves RJ, Rigby M, Smith D and Hill RG (1993) Lack of effect of L-687,414 [(+)-cis-4-methyl-HA-966, and NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol 110:36-42.
13. Hunter AJ, Green AR and Cross AJ (1995) Animal models of acute ischaemic stroke: Can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci 18:123-128.
14. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Sasamata SS and Yamaguchi T (1998) YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn-Schmiedeberg's Arch Pharmacol 358:586-591.
15. Klette KL, DeCoster MA, Moreton JE and Tortella FC (1995) Role of calcium in sigma mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 704:31-41.
16. Koizumi JY, Nakazawa TO and Ooneda G (1986) Experimental studies of ischemic brain edema. I: A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 8:1-8.
17. Kuroiwa T, Shibutani M and Okeda R (1988) Blood-brain disruption and exacerbation of ischemic brain edema after restoration of blood flow in experimental focal cerebral ischemia. Acta Neuropathol 76:62-70.
18. Longa EZ, Weinstein PR, Carlson S and Cummings R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91.
19. Lu X-CM, Tang Z, Liu W, Lin O and Slusher BS (1998) N-Acetyl-aspartyl-glutamate (NAAG) protects against focal cerebral ischemia in a rat model of MCAo. Neurosci Abstr 24:581.
20. Margaill I, Parmentier S, Callebert J, Allix M, Boulu RG and Plotkine M (1996) Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J Cereb Blood Flow Metab 16:107-113.
21. Marquis KL, Paquette NC, Gussio RP and Moreton JE (1989) Comparative electroencephalographic and behavioral effects of phencyclidine, (+)-SKF-10,047 and MK-801 in rats. J Pharmacol Exp Ther 281:1104-1112.
22. Muir KW and Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513.
23. Nehls DG, Park CK, MacCormack AG and McCulloch J (1990) The effects of N-methyl-D-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilization. Brain Res 511:271-279.
24. Newman AH (1996) Dextromethorphan, carbetapentane, and analogs as anticonvulsant and neuroprotectant agents, in Studies Medicinal Chemistry (Vol 1; Choudhary MI ed) pp 331-353, Harwood Academic, Switzerland.
25. Newman AH, Bevan K, Bowery N and Tortella FC (1992) Synthesis and evaluation of 3-substituted-17-methylmorphinan analogs as potential anticonvulsant agents. J Med Chem 35:4135-4142.
26. 1 ligands based on dextromethorphan. Med Chem Res 6:102-117.
27. Palmer GC, Cregan EF, Borrelli AR and Willett F (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann NY Acad Sci 765:236-247.
28. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN and Thron A (1992) Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 42:289-298.
29. Rogawski MA (1992) The NMDA receptor, NMDA antagonists and epilepsy therapy: A status report. Drugs 44:279-292.
30. Rogawski MA (1993) Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331.
31. Szatkowski M and Attwell D (1994) Triggering and execution of neuronal death in brain ischemia: Two phases of glutamate release by different mechanisms. Trends Neurosci 17:359-365.
32. Tallarida JJ and Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York.
33. + channels as targets for neuroprotective drugs. Trends Pharmacol Sci 16:309-316.
34. Tortella FC and Hill RG (1996) EEG seizure activity and behavioral neurotoxicity produced by (+)-MK801, but not the glycine site antagonist L-687,414, in the rat. Neuropharmacology 35:441-448.
35. Tortella FC, Klette KL, DeCoster MA, Davis BJ and Newman AH (1995) Dextromethorphan analogs are neuroprotective in vitro and block glutamate-induced excitotoxic calcium signals in neurons. Neurosci Lett 198:79-82.
36. Tortella FC, Lu X-M, Britton P, Laakosky M, Rose J, Robles L, DeCoster M and Newman AH (1997a) AHN-649, a novel analog of dextromethorphan, is neuroprotective and improves recovery following global forebrain injury in rats. Pharmacol Rev Commun 9:157-163.
37. Tortella FC, Robles L, Witkin JM and Newman AH (1994) Novel anticonvulsant analogs of dextromethorphan: Improved efficacy, potency, duration and side-effect profile. J Pharmacol Exp Ther 268:727-733.
38. Tortella FC, Rose J, Robles L, Moreton JE, Hughes J and Hunter JC (1997b) EEG Spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. J Pharmacol Exp Ther 282:286-293.
39. Whetsell WO (1996) Current concepts of excitotoxicity. J Neuropathol Exp Neurol 55:1-13.
40. Xue D, Huang ZG, Smith KE and Buchan AM (1992) Immediate or delayed mild hypothermia prevents focal cerebral infarction. Brain Res 587:66-72.
41. Yang GY and Betz L (1994) Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke 25:1658-1665.
42. Zhang RL, Chopp M, Zarow GJ, Graham SH and Weinstein PR (1994) Postischemic (1 hour) hypothermia significantly reduces ischemic cell damage in rats subjected to 2 hours of middle cerebral artery occlusion. Stroke 24:1235-1240.